GGrantIndex
← Leaderboards

Jamy D Ard

University Of Alabama At Birmingham

$10,802,351
Attributed
$22,670,335
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.4M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$26,598,286 · 15

By mechanism

UM1$7,981,899 · 1
UH3$6,684,343 · 1
UL1$3,927,951 · 1
R01$2,774,026 · 1
U01$1,868,909 · 1
UG3$1,766,159 · 1

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Obesity

Research focus

ObesityBody Weight DecreasedWeightHypertensionBlood PressureParticipantLipidsFatty Acid Glycerol EstersPrimary OutcomeCardiovascular Disorder RiskRisk FactorsUnited StatesDiabetes MellitusMaintenanceProgramsBody WeightDesignFundingAdultDietBody Mass IndexEffectivenessCardiovascular SystemAmerican

Grant awards (29)

CTSA UM1 Program at Wake Forest$3,951,899
UM1 · FY2025 · TR
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,509,689
UH3 · FY2025 · HL
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery$563,850
U01 · FY2025 · AR
CTSA UM1 Program at Wake Forest$4,030,000
UM1 · FY2024 · TR
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,515,457
UH3 · FY2024 · HL
Wake Forest Clinical and Translational Science Award$3,927,951
UL1 · FY2023 · TR
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,810,070
UH3 · FY2023 · HL
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery$644,282
U01 · FY2023 · AR
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,849,127
UH3 · FY2022 · HL
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery$660,777
U01 · FY2022 · AR
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,766,159
UG3 · FY2021 · HL
Calorie Restriction & Body Composition, Function, & QoL in Older Adults$485,100
R01 · FY2013 · AG
Calorie Restriction & Body Composition, Function, & QoL in Older Adults$544,917
R01 · FY2012 · AG
Calorie Restriction & Body Composition, Function, & QoL in Older Adults$565,585
R01 · FY2011 · AG
Calorie Restriction & Changes in Body Composition, Disease, Function, & QoL in Ol$580,831
R01 · FY2010 · AG
Calorie Restriction & Changes in Body Composition, Disease, Function, & QoL in Ol$597,593
R01 · FY2009 · AG
Improving Weight Loss Outcomes in African Americans$154,729
K23 · FY2008 · DK · contact PI
THE DINE STUDY - DIET INTERVENTION TO NEGATE DIABETES STUDY$564,928
M01 · FY2007 · RR · contact PI
Improving Weight Loss Outcomes in African Americans$155,647
K23 · FY2007 · DK · contact PI
THE ADAPT HYPERTENSION STUDY$21,313
M01 · FY2007 · RR · contact PI
EATRIGHT FOR LIFE$15,223
M01 · FY2007 · RR · contact PI
EATRIGHT FOLLOW UP STUDY$10,518
M01 · FY2007 · RR · contact PI
THE DINE STUDY - DIET INTERVENTION TO NEGATE DIABETES STUDY$167,087
M01 · FY2006 · RR · contact PI
Improving Weight Loss Outcomes in African Americans$155,572
K23 · FY2006 · DK · contact PI
EATRIGHT FOLLOW UP STUDY$14,100
M01 · FY2006 · RR · contact PI
THE ADAPT HYPERTENSION STUDY$12,925
M01 · FY2006 · RR · contact PI
EATRIGHT FOR LIFE$7,520
M01 · FY2006 · RR · contact PI
Improving Weight Loss Outcomes in African Americans$157,794
K23 · FY2005 · DK
Improving Weight Loss Outcomes in African Americans$157,643
K23 · FY2004 · DK